Ovarian Cancer Trial, Recruiting NCT06665945 Sponsor: University of Utah Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT06665945
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

This trial has three groups. The criteria for each group are listed below.

Groups 1 and 2 – Women recently diagnosed with an ovarian or pelvic mass:

  • Women aged 21 years or older
  • People who have been diagnosed with any type of ovarian or pelvic mass
  • People who have not yet received any treatment for ovarian cancer (if cancer has already been diagnosed)
  • People whose doctor is planning to carry out a biopsy, surgery, or other diagnostic procedure to investigate the ovarian or pelvic mass (if a diagnosis has not already been made before joining the trial)

Group 3 – Women without ovarian cancer (a comparison group):

  • Women aged 21 years or older who do not have ovarian cancer

Who may not be able to join:

Groups 1 and 2 – Women recently diagnosed with an ovarian or pelvic mass:

  • People who currently have another active cancer
  • People who have been diagnosed with any other cancer in the last 6 months (except certain skin cancers or a very early-stage cervical condition known as carcinoma in situ)
  • People who have received treatment for any other cancer in the last 6 months (except certain skin cancers or carcinoma in situ of the cervix — note that some ongoing hormone-based or maintenance therapies may still be allowed; confirm with trial site)
  • People who are currently receiving chemotherapy, radiation, or other active treatments for ovarian cancer
  • People who have already had their ovarian mass completely removed
  • People who are unable to provide a blood sample

Group 3 – Women without ovarian cancer:

  • People who currently have an active cancer, or who have been diagnosed with any cancer in the last 6 months (except certain skin cancers or carcinoma in situ of the cervix)
  • People who have received treatment for any cancer in the last 6 months (except certain skin cancers or carcinoma in situ of the cervix)
  • People who have been hospitalised or had surgery (other than minor procedures such as mole removal) in the last 8 weeks
  • People with significantly reduced kidney function or who are on dialysis (confirm with trial site)
  • People with significant liver problems, including liver failure, cirrhosis, or certain abnormal liver test results (confirm with trial site)
  • People with advanced or severe heart failure (confirm with trial site)
  • People with poorly managed diabetes, indicated by a blood sugar control marker above a certain level (confirm with trial site)
  • People who have had a blood clot in a vein, a heart attack, or a stroke in the last 8 weeks
  • People who are currently pregnant or have been pregnant in the last 12 weeks
  • People who have received a blood transfusion in the last 8 weeks
  • People with a personal history of ovarian cancer at any point in their life
  • People who have had both ovaries and fallopian tubes surgically removed
  • People who have had one or both ovaries surgically removed
  • People who are unable to provide a blood sample

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Theresa Werner, MD, Huntsman Cancer Institute/ University of Utah

Phone: 801-585-0161

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 April 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Early-Stage Ovarian Cancer Detection

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov